← All candidates
11 insider filings on record.
11 filings on record.
VTRSViatris Inc
NasdaqGS · Healthcare · $19.55B
$17.02
+2.22% · Sep 16
11 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 1 sell◆ 6 8-K
▸ hover a marker for the filing · drag to zoom · 3 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$19.55B
Float
1141.8M
99% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
6.4
Price / sales
1.3
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Executive Officer
Smith Scott Andrew
Bought $219.7K on Aug 12 — 22,000 sh @ $9.99, held direct, 7.0% of their stake.
First Form 4 on file
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
6 more transactions on Pro →Context
Earnings · EPS vs forecast
4 of 4 quarters beat
Q2 '26$0.69 act+$0.09
Q1 '26$0.59 act+$0.09
Q4 '25$0.57 act+$0.04
Q3 '25$0.67 act+$0.05
Coverage
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and ViatrisZacks · 2w agoViatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough?Simply Wall St. · 2w agoCavendish reiterates 'buy' rating on Shield Therapeutics after US deal with ViatrisProactive · 2w agoGilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention FormulationInvestorsHub · 22h ago
The file stays open
11 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice